View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 30, 2021

My Health Logic to acquire LOC technology for kidney disease diagnosis

My Health Logic, a subsidiary of Health Logic Interactive, has entered a licence agreement with an arm’s length third party (licensor) to acquire a global, exclusive licence to the UAL-Chip, a lab-on-chip (LOC) technology for kidney disease diagnosis.

My Health Logic, a subsidiary of Health Logic Interactive, has entered into a licence agreement with an arm’s length third party (licensor) to acquire a global, exclusive licence to the UAL-Chip, a lab-on-chip (LOC) technology for kidney disease diagnosis.

The UAL-Chip can potentially be used in a smartphone connected, handheld device to offer quick point-of-care (POC) chronic kidney disease (CKD) diagnosis in less than five minutes.

A life-changing chronic condition, CKD is harmful to patients and is very expensive to treat if not detected at an early stage.

My Health Logic intends to offer a low-cost, accessible tool to aid in early CKD detection and treatment for many at-risk patients.

Using microfluidic technology, the UAL-Chip can check the albumin levels of urine and provide quick results to a users’ smartphone, as well as their healthcare specialist.

My Health Logic plan to collect the data through MATLOC, their handheld POC device, which is currently in the developmental stage, and store it on a continued care platform.

LOC technology lead inventor Dr Francis Lin said: “Our lab-on-chip platform can give accurate results rivalling central laboratories in precision but in an accessible, low cost and rapid form usable in the home, fulfilling the dream of true point-of-care diagnosis and personalised medicine.”

Under the terms of the licence agreement, My Health Logic will pay annual royalties on the net sales of licensed products to the licensor, as well as paying previous patent costs, annual licence maintenance fees and certain amounts at regulatory approval process milestones.

They will also develop, manufacture and market products that incorporate the licensed technology, marketing such products in the US and Canada within six months of receiving regulatory approval.

The company did not disclose the financial details of the agreement.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network